Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments

Contributed by: Business Wire

Logo

Tags

Research

Mental Health

FDA

Clinical Trials

Public Policy/Government

Biotechnology

White House/Federal Government

Pharmaceutical

Health

Science

psilocybin COMP360

More Like This

Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials

Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights

Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 2026

Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher

Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit